UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                    Form 8-K/A

                                 Current Report

                       Pursuant to Section 13 or 15(d) of
                           The Securities Act of 1934



Date of Report (Date of earliest event reported)                       
                                              August 26, 1998 (August 20, 1998)



                             MYLAN LABORATORIES INC.
             (Exact name of registrant as specified in its charter)



Pennsylvania                1-9114                           25-1211621
  (State or other         (Commission                  (I.R.S. Employer
  jurisdiction of        File Number)               Identification No.)
  incorporation)



                               130 Seventh Street
                              1030 Century Building
                                 Pittsburgh, PA                      15222
                   (Address of principal executive offices)        (Zip Code)


Registrant's telephone number, including area code               (412) 232-0100








Item 5.  Other Events.

     As previously  reported,  on June 24, 1998,  Mylan  Laboratories  Inc. (the
"Company")   entered  into  an  Agreement  and  Plan  of  Merger  with  Penederm
Incorporated  ("Penederm")  and a subsidiary  of the  Company.  If the merger is
consummated upon the terms proposed, each share of common stock of Penederm will
be exchanged  for 0.68 shares of common stock of the Company,  and Penederm will
become a wholly-owned subsidiary of the Company.

     On August 20,  1998,  the Company  filed with the  Securities  and Exchange
Commission a registration statement on Form S-4 to register the 6,791,216 shares
of its common stock proposed to be issued to the  stockholders  of Penederm upon
consummation of the merger.  The registration  statement includes the prospectus
of the Company and the proxy  statement of Penederm for a special meeting of its
stockholders  proposed  to be held  to  consider  approval  of the  merger.  The
Company's  shares will be offered  only by means of the  prospectus.  Penederm's
solicitation  of proxies  will not  commence  unless and until the  registration
statement is declared  effective by the Securities and Exchange  Commission.  As
previously  reported,  the  merger is  subject  to the  satisfaction  of various
conditions.

     In addition,  the Company  previously  reported in its Quarterly  Report on
Form  10-Q  that  a  request  made  by  Key  Pharmaceuticals  for a  preliminary
injunction  in  its  lawsuit  with  the  Company  related  to  marketing  of its
nitroglycerin  transdermal system had been denied. The Company has since learned
that, while Key Pharmaceuticals'  request was not granted at the hearing held to
consider  the matter,  the Court has  deferred the decision as to whether or not
the preliminary  injunction should be granted.  The Company continues to believe
that this suit is without merit and intends to vigorously defend its position.



                                    SIGNATURE

         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  Registrant  has duly  caused  this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                          MYLAN LABORATORIES INC.

                                                 /s/ Donald C. Schilling
                                          Donald C. Schilling
                                          Vice President of Corporate Finance


Date:        August 26, 1998
             Pittsburgh, Pennsylvania